137 related articles for article (PubMed ID: 15015578)
1. Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine).
Farinha NJ; Shaker S; Lemaire M; Momparler L; Bernstein M; Momparler RL
Anticancer Res; 2004; 24(1):75-8. PubMed ID: 15015578
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
3. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Schmelz K; Wagner M; Dörken B; Tamm I
Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
[TBL] [Abstract][Full Text] [Related]
5. [Growth and gene expression of leukemia cell after treated with methylation inhibitor 5-aza-2'-deoxycytidine].
Qiao SK; Xu SR; Guo XN
Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):486-90. PubMed ID: 15555266
[TBL] [Abstract][Full Text] [Related]
6. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
Tamm I; Wagner M; Schmelz K
Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL
Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212
[TBL] [Abstract][Full Text] [Related]
8. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
[TBL] [Abstract][Full Text] [Related]
11. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effect on proliferation of KG1a cell line by methyltransferase inhibitors].
Chen H; Wu SL; Zhu Q; Shi YJ; Xu GB; Wang JZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):289-93. PubMed ID: 12513759
[TBL] [Abstract][Full Text] [Related]
14. 5-Aza-2'-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73.
Liang W; Xia H; Li J; Chunhua Zhao R
J Pediatr Hematol Oncol; 2012 Mar; 34(2):108-15. PubMed ID: 22278203
[TBL] [Abstract][Full Text] [Related]
15. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
[TBL] [Abstract][Full Text] [Related]
17. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells.
Shaker S; Bernstein M; Momparler RL
Oncol Rep; 2004 Jun; 11(6):1253-6. PubMed ID: 15138563
[TBL] [Abstract][Full Text] [Related]
19. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
20. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
